The summaries are free for public
use. The Chronic Liver Disease
Foundation will continue to add and
archive summaries of articles deemed
relevant to CLDF by the Board of
Trustees and its Advisors.
Abstract Details
Residual low HDV viremia is associated HDV RNA relapse after PEG-IFNa-based antiviral treatment of hepatitis delta: Results from the HIDIT-II study
Liver Int. 2020 Nov 20. doi: 10.1111/liv.14740. Online ahead of print.
Birgit Bremer1, Olympia Anastasiou2, Svenja Hardtke34, Florin Alexandru Caruntu5, Manuela G Curescu6, Kendal Yalcin7, Ulus S Akarca8, Selim Gürel9, Stefan Zeuzem10, Andreas Erhardt11, Stefan Lüth12, George V Papatheodoridis13, Monica Radu5, Ramazan Idilman14, Michael P Manns14, Markus Cornberg14, Cihan Yurdaydin1415, Heiner Wedemeyer1416
Author information
1Dept. of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Germany.
2Institute for Virology, Essen University Hospital and Medical Faculty of the University of Duisburg, Essen, Germany.
3University Medical Centre Hamburg-Eppendorf, Hamburg, Germany.
4German Center for Infectious Disease Research (DZIF), HepNet Study-House, Hannover, Germany.
5National Institute for Infectious Diseases Prof.Dr.Matei Bals, Bucharest, Romania.
6Spitalul Clinic de Boli Infectioase si, Timisoara, Romania.
7Dicle University Medical Faculty, Diyarbakir, Turkey.
8Ege University Medical Faculty, Izmir, Turkey.
9Uludag University Medical Faculty, Bursa, Turkey.
10Johann Wolfgang Goethe University Medical Center, Frankfurt/Main, Germany.
11Heinrich Heine University, Düsseldorf, Germany.
12Center of Internal Medicine II, University Hospital Brandenburg, Brandenburg Medical School, Brandenburg, Germany.
13School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.
14Department of Gastroenterology, Ankara University Medical School, Ankara, Turkey.
15Department of Gastroenterology and Hepatology, Koç University Medical School, Istanbul, Turkey.
16Dept. of Gastroenterology and Hepatology, Essen University Hospital and Medical Faculty of the University of Duisburg, Essen, Germany.
Abstract
The role of low levels of HDV-RNA during and after interferon therapy of hepatitis D is unknown. We re-analyzed HDV RNA in 372 samples collected in the HIDIT-2 trial (Wedemeyer et al., Lancet Infectious Diseases 2019) with the Robogene assay (RA; Jena Analytics). Data were compared with the previously reported in house assay (IA). We detected HDV-RNA in one third of samples previously classified as undetectable using the highly-sensitive RA. Low HDV viremia detectable at week 48 or week 96 was associated with a high risk for post-treatment relapse, defined as HDV RNA positivity in both assays at week 120. HDV RNA relapses occurred in 10/15 (67%) patients with detectable low HDV RNA at week 48 and in 10/13 (77%) patients with low viremia samples at week 96. In contrast, the post-treatment relapse rate was lower in patients with undetectable HDV RNA in both assays during treatment.